sorafenib has been researched along with Di Guglielmo Disease in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Mori, M; Sprague, J | 1 |
| Brown, P; Leahy, D; Levis, M; Li, L; Nguyen, B; Small, D; Williams, AB | 1 |
2 other study(ies) available for sorafenib and Di Guglielmo Disease
| Article | Year |
|---|---|
The successful remission induction by sorafenib and long-term complete remission in a FLT3-ITD-positive patient with a refractory acute erythroid leukemia and abnormal cytogenetics.
Topics: Abnormal Karyotype; Antineoplastic Agents; Benzenesulfonates; Cytogenetic Analysis; Drug Resistance, Neoplasm; Erythroid Cells; Female; fms-Like Tyrosine Kinase 3; Gene Duplication; Humans; Leukemia, Erythroblastic, Acute; Middle Aged; Niacinamide; Phenylurea Compounds; Pyridines; Remission Induction; Sorafenib; Tandem Repeat Sequences; Time Factors; Treatment Outcome | 2012 |
Mutations of FLT3/ITD confer resistance to multiple tyrosine kinase inhibitors.
Topics: Animals; Benzenesulfonates; Blotting, Western; Cells, Cultured; Drug Resistance, Neoplasm; fms-Like Tyrosine Kinase 3; Humans; Immunoprecipitation; Leukemia, Erythroblastic, Acute; Mice; Mice, Inbred BALB C; Mutation; Niacinamide; Phenylurea Compounds; Phosphorylation; Precursor Cells, B-Lymphoid; Protein Kinase Inhibitors; Pyridines; Sorafenib; Tandem Repeat Sequences | 2013 |